Safety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151
Year: 2018
Type: article
Abstract: Background: Atezo (anti–PD-L1) + bev (anti-VEGF) demonstrated improved PFS and favourable safety vs sun in Ph II and III trials in patients (pts) with untreated mRCC (McDermott 2018; Motzer ASCO GU 2018). To further explore the improved tolerability with this regimen, we performed additional safety analyses using pooled data from the atezo + bev and sun arms of these studies.
Source: Annals of Oncology
Institutions: Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Institut Gustave Roussy, Fondation Gustave Roussy, Georgetown University, Georgetown Lombardi Comprehensive Cancer Center, Queen Mary University of London, The Royal Free Hospital, Barts Cancer Institute, Cleveland Clinic, Memorial Sloan Kettering Cancer Center, City Of Hope National Medical Center, City of Hope, University of California, San Francisco, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Genentech, Roche (Switzerland), Aarhus University Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2896908167